I would listen to the call. Davis compares it to some other drug already on the market and says that aplindore does not work as well and has more side effects. We really should have sold it after phase IIa. I should have known they would find a way to screw this up....just like adipiplon.

I would guess the phase I-II data is worth maybe $1-3M and maybe someone will pick it up to test for another indication?